Michael S Gordon
6PUBLICATIONS
63CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (6)
Sort by Publication Date:
|Mar 05, 2026
BET inhibitor OPN-2853 in advanced solid tumors and lymphoma: results from the phase 1b PLX124-01 trial.Michael S Gordon, Richard D Carvajal, Alexander Spira
|Jan 27, 2026
Correlative Biomarker Analysis of PSMA Expression on CTCs and PSMA Imaging in a Phase I Study of PSMA-Targeted Tubulysin Conjugate EC1169.Samir Zaidi, Phillip H Kuo, Tiago Paiva Prudente
|Jan 27, 2025
Botensilimab (Fc-enhanced anti-cytotoxic lymphocyte-association protein-4 antibody) Plus Balstilimab (anti-PD-1 antibody) in Patients With Relapsed/Refractory Metastatic Sarcomas.Breelyn A Wilky, Gary K Schwartz, Michael S Gordon
|Jun 14, 2022
First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors.Tae Won Kim, Howard A Burris, Maria J de Miguel Luken
|Jul 28, 2021
Phase I Open-Label Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Dilpacimab in Patients with Advanced Solid Tumors.Michael S Gordon, John Nemunaitis, Minal Barve
|May 31, 2020
Safety and efficacy of CDX-014, an antibody-drug conjugate directed against T cell immunoglobulin mucin-1 in advanced renal cell carcinoma.Bradley A McGregor, Michael Gordon, Ronan Flippot
Pageof 1
Frequent Collaborators
1 joint publications
Bradley A McGregor
1 joint publications
Ronan Flippot
1 joint publications
Neeraj Agarwal
1 joint publications
Saby George
1 joint publications
David I Quinn
1 joint publications
Tibor Keler
1 joint publications
Toni K Choueiri
1 joint publications
Tae Won Kim
1 joint publications
Maria J de Miguel Luken
1 joint publications
Michael J Pishvaian
